Mycophenolate Mofetil-d4 (hydrochloride)

Mycophenolate Mofetil-d4 (hydrochloride)

• UNSPSC Description: Mycophenolate Mofetil-d4 hydrochloride is deuterated labeled Mycophenolate mofetil hydrochloride (HY-B0199A). Mycophenolate mofetil (RS 61443) hydrochloride is a immunosuppressant, a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPD) type I/II with IC50s of 39 nM and 27 nM, respectively.
• Target Antigen: Bacterial; Endogenous Metabolite; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Metabolic Enzyme/Protease;Others
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Solubility: 10 mM in DMSO
• Smiles: C/C(CCC(OC([2H])(C([2H])(N1CCOCC1)[2H])[2H])=O)=C\CC(C(O)=C2C(OCC2=C3C)=O)=C3OC.Cl
• Molecular Weight: 473.98
• References & Citations: [1]Nakanishi, T., et al., Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection. Int Immunopharmacol, 2010. 10(1): p. 91-7.|[2]Dehghani, F., et al., Inhibition of microglial and astrocytic inflammatory responses by the immunosuppressant mycophenolate mofetil. Neuropathol Appl Neurobiol, 2010. 36(7): p. 598-611.|[3]Ozgen, M., et al., Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin Exp Dermatol, 2012. 37(1): p. 48-54.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported